ArticleMicroorganisms2026
G-HIV: An Integrated Long-Read Sequencing and Automated Bioinformatics Platform for Rapid and Precise HIV-1 Surveillance.
Article in Microorganisms, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The accurate characterization of human immunodeficiency virus (HIV) genetic diversity and drug resistance is critical for effective surveillance and treatment, yet current sequencing technologies face limitations in sensitivity and scalability for community-level implementation. We present G-HIV, an integrated platform combining long-read sequencing (G-seq500) with an automated bioinformatics pipeline. G-HIV processes raw FastQ data to generate automated reports on point mutations, drug resistance predictions, viral quasispecies diversity, and haplotype networks via a two-step analytical approach. Applied to 44 HIV-1 plasma samples (42 used in the final comparison after excluding 2 samples with low-quality Sanger chromatograms), G-HIV detected 3-48 candidate minority variants per sample that were not observed by Sanger sequencing, identifying drug-resistant quasispecies in two samples with undetectable Sanger signals, and revealed mixed infection cases (e.g., inter-subtype CRF07_BC/CRF08_BC) through phylogenetic analysis. G-HIV addresses an integration of long-read sequencing with a fully automated, one-stop bioinformatics pipeline designed for frontline laboratories without specialized bioinformatics expertise-providing a scalable solution for community-based resistance surveillance and personalized therapy optimization in resource-limited settings. This research addresses an integrated long-read sequencing and automated bioinformatics platform for rapid and precise HIV-1 surveillance. G-HIV surpasses conventional approaches like Sanger sequencing in resolution, efficiency, and accessibility for community-level surveillance. By integrating long-read sequencing, streamlining workflows and eliminating the need for specialized bioinformatics expertise, G-HIV is positioned to become a new solution, providing more effective one-stop services for HIV-1 prevention and control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.